JMI LABS IS NOW PART OF LEARN MORE

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) by MA Pfaller, MD Huband, PR Rhomberg, PA Bien, and M Castanheira in Antimicrob Agents Chemother 66:100 (2022), aac.01028-22.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals. Lead Author: Rodrigo E. Mendes. Presented at IDWeek 2022, October 19-23, Washington DC.

Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin

Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin by Arendrup MC, Arikan-Akdagli S, Castanheira M, Guinea J, Locke JB, Meletiadis J, Zaragoza O in J. Antimicrob. Chemother. (2022); dkac373.

In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020)

In vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020) by Mendes RM, Hubler C, Kimbrough JH, Critchley I, Cotroneo N, Castanheira in Antimicrob. Agents Chemother. 66:10 (2022); aac.01214-22.

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) by Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, and Castanheira M in J. Antimicrob. Chemother. 77 (2022); 2642-2649.

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata by Carvalhaes CG, Rhomberg PR, Pfaller MA, Locke JB, Castanheira M in Mycoses 65 (2022); 1040-1044.

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020) by Sader HS, Castanheira M, Duncan LR, Mendes RE in Diagnostic Microbiology and Infectious Disease 105:1(2023), 115820.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States Lead Author: SJ Ryan Arends presented at IDWeek 2022, October 19-23, Washington DC

Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other β-Lactam Agents

Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other
β-Lactam Agents. Lead author: Mariana Castanheira. IDWeek 2022. October 19-21. Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021)

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021)

In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals. Lead author: Rodrigo Mendes. Presented at IDWeek 2022. October 19-21, 2022. Washington DC.

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units in US Medical Centers (2010–2019)

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units
in US Medical Centers (2010–2019). Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021)

Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021

Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021. Lead author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020)

Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

 

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021)

Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020–2021). Lead author: Helio Sader, IDWeek 2022, October 19-23, Washington DC.

Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021)

Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021). IDWeek 2022. October 19-21, 2022. Washington DC.

Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program

Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program. Lead Author: Gauri Deshpande; Presented by: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals

Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals. Lead Author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021)

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). Lead Author: HS Sader at IDWeek 2022, October 19-23, Washington DC.

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type

In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type. Lead Author: Mike Huband, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States. Lead author: SJ Ryan Arends. IDWeek 2022. October 19-21. Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations

In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations. Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States

Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the
United States. Lead Author: Rodrigo Mendes. IDWeek 2022. October 19-21, 2022. Washington DC.

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/ β-Lactamase Inhibitor Combinations Against These Isolates

Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/
β-Lactamase Inhibitor Combinations Against These Isolates. Lead author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021)

Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)

Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019). Lead author: Cecilia G Carvalhaes, IDWeek 2022, October 19-23, Washington DC.

Activity of Meropenem-Vaborbactam and Comparators Against Enterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States

Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals. Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric Patients from US Medical Centers (2020–2021)

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric
Patients from US Medical Centers (2020–2021). Lead author: Helio Sader. IDWeek 2022. October 19-21. Washington DC.

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021). Lead Author: Michael Huband, IDWeek 2022, October 19-21, Washington DC.

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021)

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021). Lead author: Cecilia Carvalhaes, IDWeek 2022, October 18-21, Washington DC.

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents by Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS in JAC-Antimicrob. Resist. 2022; 4(5): dlac098.

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe by Shortridge D, Deshpande L, Streit J, and Castanheira M in JAC – Antimicrob. Resist. 2022; 4 (5): dlac097.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019)

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019) by Pfaller MA, Mendes RE, Streit JM, Carvalhaes, CG in Diagnostic Microbiology and Infectious Disease 2022; 104: 115804.

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020)

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020) by Sader HS, Castanheira M, Carvalhaes CG, Arends SJR, Mendes RE in Microbial Drug Resistance 2022; 28 (9): 935-940.

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries. Lead author: SJ Ryan Arends, presented by C Ress at German Society for Urology 2022, September 21-24, Hamburg, Germany

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019)

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019) by Carvalhaes CCG, Sader HS, Rhomberg PR, Castanheira M, DeVries S, Mendes RE in Pediatr. Infect. Dis. J. 41(9):2022, 731-735.

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018 by Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M in J. Glob. Antimicrob. Resist. 31 (2022): 98-103.

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme by Carvalhaes CG, Sader HS, Streit JM, Mendes RE in JAC-Antimicrob. Resist. 4(5): 2022, dlac088

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii by Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, Cohen-Kutner M, Bachnoff N in antibiotics 11 (2022): 201.

Rezafungin In vitro Activity against Candida spp. causing Invasive Infections in Hematology/Oncology and Transplant Units Worldwide (2014-2021)

Rezafungin in vitro activity against Candida spp. causing invasive infections in hematology/oncology and transplant units worldwide (2014-2021). Lead Author: Cecilia Carvalhaes. Presented at International Immunocompromised Host Society (ICHS 2022), Basel, Switzerland, 8-11 September 2022.

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications by Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup, MC on behalf of the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) in J. Antimicrob. Chemother. 10:2022, dkac61.